We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
The FDA is requiring Wyeth to conduct a 12-month safety trial for Pristiq to secure approval of the product for the treatment of vasomotor symptoms associated with menopause, the company announced July 31.